Navigation Links
ADA Informs Patients About Osteoporosis Medications and Oral Health

ADA creates brochures with National Osteoporosis Foundation

CHICAGO, March 9 /PRNewswire-USNewswire/ -- Dental patients who have been alarmed or confused by recent news reports about how osteoporosis medications might affect their oral health now have a brochure to help them separate fact from fiction. The American Dental Association (ADA) collaborated with the National Osteoporosis Foundation to create the brochure, "Osteoporosis Medications and Your Dental Health," which will be available in dental offices this month.

The brochure explains that some patients who have taken bisphosphonates, a common class of drugs taken by those with osteoporosis or low-bone density, have developed bisphosphonate-associated osteonecrosis of the jaw. Osteonecrosis of the jaw is a rare but serious condition that can cause severe damage to the jawbone. This condition is diagnosed in patients who have an area of exposed bone in the jaw that persists for more than eight weeks, who have no history of radiation therapy to the head and neck and who are taking, or have taken, a bisphosphonate medication.

The chance of developing osteonecrosis of the jaw for patients who take bisphosphonates is unknown; however researchers agree that the chance appears to be very small. In fact, 94 percent of people diagnosed with osteonecrosis of the jaw are cancer patients who are or have received repeated high doses of bisphosphonates intravenously. The remaining 6 percent diagnosed with osteonecrosis of the jaw took oral bisphosphonates.

"Patients who take bisphosphonates for osteoporosis are encouraged to talk to their dentist so that their dentist can show them good oral hygiene practices as well as monitor their oral health," says Matthew Messina, D.D.S., ADA Consumer Advisor and a general dentist based in Ohio. "Patients should not stop taking their osteoporosis medications without speaking with their physicians."

According to the ADA, the benefits of osteoporosis medications greatly outweigh the risks of developing osteonecrosis of the jaw.

Osteoporosis is a serious condition that causes 2 million bone fractures a year, according to the National Osteoporosis Foundation. Half of women and 20 percent of men older than 50 will break a bone due to osteoporosis. Bisphosphonates are commonly prescribed to prevent broken bones. Common bisphosphonate medications include alendronate (Fosamax(R)), ibandronate (Boniva(R)), risedonate (Actone(R)) and zoledronic acid (Reclast(R)).

The "Osteoporosis Medications and Your Dental Health" brochures will be available in dental offices or for purchase by dentists on the ADA's Web site at For more information about osteonecrosis of the jaw, please visit the ADA's Web site at or the National Osteoporosis Foundation's Web site at

About the American Dental Association

Celebrating its 150th anniversary, the not-for-profit ADA is the nation's largest dental association, representing more than 157,000 dentist members. The premier source of oral health information, the ADA has advocated for the public's health and promoted the art and science of dentistry since 1859. The ADA's state-of-the-art research facilities develop and test dental products and materials that have advanced the practice of dentistry and made the patient experience more positive. The ADA Seal of Acceptance long has been a valuable and respected guide to consumer dental care products. The monthly Journal of the American Dental Association (JADA) is the best-read scientific journal in dentistry. For more information about the ADA, visit the Association's Web site at

SOURCE American Dental Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. LegalView Informs Readers of New Criminal Probe Involving Peanut Butter Recall Salmonella Poisonings
2. LegalView Informs Parents of Crib Recall Following Several Infant Deaths Caused by Asphyxiation from Improper Crib Mechanisms
3. LegalView Informs Chantix Patients of Risk of Seizures Leading to Traffic Accidents
4. LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis
5. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
6. Math battling cancer, deciding lifes challenges lead list as INFORMS meet in Seattle
7. Nasdaq Informs Synutra that the Companys Filing Delinquency has been Cured
8. Ecstasy could help patients with post-traumatic stress disorder
9. Diabetes and Elevated Levels of Cholesterol Linked to Faster Cognitive Decline in Alzheimer's Patients
10. New DNA Test Is Basis for Groundbreaking IVF Refund Plan, Easing Financial Burden for Patients
11. Saving heart attack patients in the middle of the night
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... Califia Farms ... announced that its iconic bottle has won top honors in Beverage World Magazine’s Global ... Company also announced that it has been selected as a 2015 U.S.A. Taste Champion ...
(Date:12/1/2015)... MD (PRWEB) , ... December 01, 2015 , ... ... salmon identification tests to continue the expansion of the company’s growing product line ... – for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to ...
(Date:12/1/2015)... ... December 01, 2015 , ... The ... been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable ... Meeting from November 29 to December 4, 2015. , MED-TAB is expected ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... is everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ ... next product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... today announced it has been awarded a fixed price per sprint agile development ... contract, valued at $34 million over five years, provides software engineering, infrastructure, as ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 --> ... Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, ... and Pipeline Analysis - Global Forecast to 2020", published by ... USD 73,529.2 Million by 2020 from USD 40,281.6 Million in ... Browse 37 market data ...
(Date:12/1/2015)... BANGALORE, India and PITTSBURGH ... TASE: MYL) today announced that it expects to be ... developing country markets funded by international donors, TLE400 (Tenofovir ... Efavirenz 400 mg) for $99 per patient, per year. ... to develop TLE400. The significantly reduced price could generate ...
(Date:12/1/2015)... , Dec. 1, 2015  AccuTEC Blades, a ... new corporate logo and brand identity program. The ... and engineering of bladed products where "the edge ... --> Serving manufacturers and distributors ... auto glass equipment, AccuTEC,s product lines include those ...
Breaking Medicine Technology: